D016

D016 is a **preclinical recombinant hyaluronidase enzyme candidate** developed by **Pharmact Pharmaceuticals** as a non-PEGylated enzyme with combined **PH20 and HYAL4-like activity**. It is designed to degrade **hyaluronic acid** and, based on company and publication context, also cleave **sulfated chondroitin sulfate** in the extracellular matrix. The program is positioned less as a conventional finished drug product and more as an **OEM/API enzyme platform** for pharmaceutical and cosmetic applications, with claimed higher enzymatic activity than ALT-B4 and manufacturing in Germany under cosmetic and pharmaceutical quality standards. Published preclinical work also suggests exploration of this dual-active recombinant hyaluronidase in models of **atherosclerotic lesions**.

Other names

recombinant hyaluronidaseEnzyme Innovation